Biogen Inc

Biogen’s Q4 2025 earnings reveal cost‑cutting tactics amid patent cliffs, a shift toward Alzheimer’s and rare‑disease drugs, and a focus on patient‑centric market access strategies.

Biogen’s Q4 2025 earnings show a 5% sales dip from its MS line but strong cost cuts and new Alzheimer’s/rare‑disease revenue, positioning 2026 earnings above forecasts.

Biogen’s Q4 2023 results beat estimates, driven by Leqembi’s 42 % sales surge and a 30 % drop in Alzheimer’s decline, positioning a 2026 revenue lift to $1.75 billion.

Biogen’s LEQEMBI IQLIK subcutaneous autoinjector gains FDA priority review—boosting early Alzheimer’s access, patient adherence, and investor confidence.

Biogen’s Q4 earnings hit, high‑dose SPINRAZA approval, and patent‑cliff strategy reveal how the biotech giant balances R&D costs, market access and M&A to protect revenue and stay ahead of rivals in neurology.

Biogen gains analyst backing and China’s approval of LEQEMBI’s home‑administered autoinjector, boosting access to early Alzheimer’s treatment and showing stronger growth prospects.

Biogen’s latest update reveals EMA approval for high‑dose nusinersen and new natural‑history data on Dravet syndrome, highlighting breakthrough gene‑editing and ASO pipelines that could transform rare neurological care.

Biogen Inc. has secured regulatory approval in China for its investigational Alzheimer’s therapy, LEQEMBI, marking a significant milestone for the company’s Alzheimer’s portfolio and positioning it to capture a share of the growing market in China.

Biogen has exceeded analyst expectations in its Q2 performance, prompting a revised FY25 outlook and making its stock an attractive option for investors.

Biogen’s ZURZUVAE has been recommended for marketing authorization in the treatment of postpartum depression, marking a major breakthrough for the company and potentially boosting its stock price.